The U.S. Food and Drug Administration is requiring the makers of every GLP-1 medicine on the market, including Ozempic, Wegovy, Mounjaro and Zepbound, to add a warning about a rare eye condition that can cause sudden and sometimes permanent vision loss in one eye.
The condition is called non-arteritic anterior ischemic optic neuropathy, or NAION. According to a November 9 FDA safety communication described by FOX 5 New York, the new information will go into the Warnings and Precautions section of the drugs’ prescribing labels. The agency stressed that the risk is low, and that its review does not prove the medicines cause the condition.
What the FDA found
The decision follows a review of 126 randomized clinical trials involving more than 134,000 patients, Fox Business and Drug Topics reported. Regulators also looked at real-world data from the FDA’s Sentinel network and at adverse event reports filed after the drugs went on sale.
In the trials, about 6.4 NAION cases were seen for every 100,000 people taking a GLP-1 drug for a year. In comparison groups taking a placebo or older diabetes medicines, the figure was about 3.8 per 100,000. Real-world data showed a small but statistically notable increase compared with another class of diabetes pills, DPP-4 inhibitors, according to FOX 5.
Even so, the agency said the findings “do not establish a causal link,” Fox Business reported. One reason the picture is murky: many of the people who take these medicines already have conditions that raise NAION risk on their own, including diabetes, high blood pressure and sleep apnea.
FOX 5 reported that NAION cases have been reported for every GLP-1 product now sold in the U.S. The drugs named include semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda) and the newer pill orforglipron (Foundayo).
Background: a question raised in 2024
Concerns about GLP-1 drugs and vision first drew wide attention after a July 2024 medical study linked semaglutide to this type of optic nerve damage. Scientists have been studying the question since, Fox Business reported.
Regulators in Europe moved earlier. Drug Topics noted that the European Medicines Agency has said semaglutide is associated with roughly a twofold increase in NAION risk in adults with type 2 diabetes. Hundreds of lawsuits have also been filed against drugmakers Novo Nordisk and Eli Lilly by patients alleging they were not warned about vision loss, the trade publication reported. Those claims have not been decided.
The new label language comes as GLP-1 drugs keep expanding into new uses. Upstormed News reported this week that a daily GLP-1 pill cut sleep apnea breathing pauses in yearlong trials, one of several studies widening interest in the medicines beyond diabetes and weight loss.
What NAION is, and the warning signs
NAION happens when blood flow to the front of the optic nerve suddenly drops. It usually causes painless vision loss in one eye, and the damage can be permanent. There is no proven treatment to reverse it, though Fox Business reported that about 43% of patients with significant vision impairment see some improvement on their own. It most often affects adults over 50, and an episode in one eye raises the chance of it happening in the other.
Symptoms described in the reports include:
- Sudden, painless loss of vision in one eye, often noticed on waking
- Blurry or hazy vision, especially in the center
- Blind spots or a “tunnel” effect
- Colors that look dull or distorted
Health guidance in the coverage was consistent: anyone who notices a sudden change in vision should contact their health care provider right away and seek prompt care from an eye specialist. Drug Topics also advised patients not to stop a prescribed medicine abruptly without first talking with their care team.
Why it matters for families
GLP-1 medicines are now part of daily life in many households, used for type 2 diabetes, weight management and other conditions. For most people the new warning does not change much day to day, because the reported risk is very small. But it gives families a clear list of symptoms to watch for, especially for older relatives or anyone who already has diabetes, high blood pressure or sleep apnea.
If you or a family member takes one of these drugs and has questions, talk with your doctor or pharmacist. They can weigh your personal risk factors and discuss whether an eye exam makes sense. This article is general information, not medical advice.
What to watch next
Drugmakers will now need to update their labels to include the NAION information. Watch for updated patient materials from manufacturers and pharmacies, further FDA data releases, and developments in the lawsuits over vision loss. Upstormed News will follow the story as it develops. For more health news, see our report on how an inherited cholesterol drug cut Lp(a) 78% but failed to prevent heart attacks.
Read more: Daily GLP-1 pill cut sleep apnea breathing pauses in yearlong trials
Does the new FDA warning change how you think about GLP-1 medicines? Share your thoughts in the comments.
Sources: Fox Business, “FDA orders new warning labels on Ozempic, Wegovy over rare risk of permanent vision loss” (November 10, 2026); Drug Topics, “FDA Adds NAION Eye Risk Warning to All GLP-1 Labels” (November 10, 2026); FOX 5 New York, “What is NAION? Ozempic, Wegovy, other GLP-1s linked to rare eye condition” (November 10, 2026)
Leave a Reply